Role of ambrisentan in the management of pulmonary hypertension

Annals of Pharmacotherapy

Volumn 42, Issue 11, 2008, Pages 1653-1659

  Hrometz, Sandra L ^a   Shields, Kelly M ^a  

^a OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

Ambrisentan; Endothelin antagonist; Pulmonary arterial hypertension; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; DIURETIC AGENT; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLYCOSIDE; ILOPROST; KETOCONAZOLE; LETAIRIS; OMEPRAZOLE; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DISEASE COURSE; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; EDEMA; EMBASE; EXERCISE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; LIVER INJURY; MEDLINE; NAUSEA; NOSE CONGESTION; OXYGEN THERAPY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PYRIDAZINES;

EID: 55949126606     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L014     Document Type: Review

References (36)

1. Gilead. Patient care. www.gilead.com/patient_care (accessed 2008 Jul 1).
2. Galie N, Rubin LJ, eds. A review of the third world symposium on pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(suppl S):1S-90S.
3. Rubin LJ. Executive summary, diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(suppl 1):4S-6S.
4. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(suppl S):40S-7S.
5. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(suppl S):13S-24S.
6. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
7. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
8. Badesch DB, Abman SH, Simonneau G, Rubin RJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28.
9. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
10. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
11. Packet insert. Letairis (ambrisentan). Foster City, CA: Gilead Sciences, Inc., February 2008.
12. Barst RJ, Langleben D, Badesch DB, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
13. Seo B, Oemar B, Siebenmann R, von Segesser L, Luscher T. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203-8.
14. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133-8.
15. De Nucci G, Thomas R, D'Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988;85:9797-800.
16. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-73. DOI 10.1172/JCI116338
17. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35.
18. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC. Function of the endothelin (B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 2002;95:221-38.
19. Lee SH, Channick RN. Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med 2005;26:402-8.
20. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol 2005;43:19-29.
21. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007;28:117-25.
22. Greene S, Nunley K, Weber S, Minobe W, Bristow MR. ETA vs. ETB receptor selectivity of endothelin-1 receptor antagonists in human myocardial membranes (abstract). J Am Coll Cardiol 2006;47(suppl):307A.
23. Olschewski H, Badesch D, Barst R, et al. Long-term safety and efficacy of ambrisentan in patients with pulmonary arterial hypertension. European Respiratory Society, Copenhagen, Denmark, September 17-21, 2005.
24. Oudiz RJ, Torres F, Frost AE, et al. ARIES-1: a placebo-controlled efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension (abstract). Chest 2006;130(suppl):121S.
25. Oudiz RJ, Torres F, Frost AE, et al. Ambrisentan in PAH - a phase 3, randomized, double-blind, placebo-controlled, multicenter, efficacy study of ambrisentan in subjects with pulmonary arterial hypertension. Presented at: CHEST: Annual International Scientific Assembly of the American College of Chest Physicians meeting. Salt Lake City, Utah, October 2006.
26. Olschewski H, Galie N, Ghofrani HA, et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study (abstract). Proc Am Thorac Soc 2006;3:A728.
27. Oudiz RJ, Olschewski H, Galie N, et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study(poster). Presented at: Pulmonary Hypertension Association International Conference and Scientific Sessions, Minneapolis, June 23-25, 2006.
28. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities (abstract). Chest 2006;130(suppl):254S.
29. Dufton C, Gerber M, Yin O, Brandquist C, Ghofrani HA. No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil (abstract). Chest 2006;130(suppl):254S.
30. Gerber M, Dufton C, Pentikis H, Zhu L, Ghofrani HA. Ambrisentan has no clinically relevant effects on the pharmacokinetics or pharmacodynamics of warfarin (abstract). Chest 2006;130(suppl):256S.
31. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8.
32. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
33. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin antagonist. Clin Pharmacokinet 2004;43:1089-115.
34. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-12.
35. Burgess G, Hoogkamer H, Collings L, Dingemanse, J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50.
36. Chase M. New option for rare condition. Wall Street Journal. http://online. wsj.com/article/SB118194484522137193.html?mod=yahoo_hs&ru= yahoo (accessed 2008 Jul 1).